Inclusion Criteria

Inclusion:

- Histologically or cytologically confirmed sarcoma

- Metastatic or unresectable disease

- Disease progressed after 1 or 2 prior treatment regimens with chemotherapy or
targeted anticancer agents such as imatinib mesylate

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension as > 10 mm

- At least 4 weeks since prior radiation or chemotherapy (6 weeks for melphalan,
nitrosoureas, or mitomycin C)

- ECOG performance status 0-2

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin < 2 mg/dL

- AST/ALT < 3 times upper limit of normal

- Creatinine clearance > 30 mL/min

- Negative pregnancy test

- Fertile patients must use effective contraception

Exclusion:

- Pregnant or nursing

- Uncontrolled concurrent illness including, but not limited to, any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Uncontrolled hypertension or hypotension

- Psychiatric illness or social situations that would limit compliance with study
requirements

- Evidence of bleeding diathesis

- Concurrent angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers

- Concurrent investigational agents for cancer treatment